Jessica Garcia

Jessica Garcia

Year:
-
Grants:
NHF-Takeda Clinical Fellowship
Author(s):
Jessica Garcia
Dr. Jessica Garcia is currently a pediatric hematology/oncology fellow at the Medical College of Wisconsin/Children's Hospital of Wisconsin. Her clinical mentor is Dr. Joan Gill, Director of the Comprehensive Center for Bleeding Disorders (CCBD) in Milwaukee, Wisconsin.  Dr. Garcia's primary research mentor will be Dr. Veronica Flood, with Dr. Bob Montgomery as her secondary research mentor. Dr. Garcia attended medical school and completed her pediatric residency at the University of Illinois College of Medicine at Peoria/Children's Hospital of Illinois. During her pediatric residency, Dr. Garcia worked with Dr. de Alarcon studying the mechanisms underlying the thrombocytosis seen with iron deficiency anemia in an animal model. As a NHF-Baxalta Clinical Fellow, Dr. Garcia will receive specialized training in hemostasis and thrombosis, available through the Comprehensive Center for Bleeding Disorders (CCBD) and Blood Research Institute (BRI). Her research will focus on the biology of von Willebrand factor.
Mechanisms and Therapeutic Strategies Targeting TAFI-mediated Vascular Remodeling in Hemophilic Arthropathy

Mechanisms and Therapeutic Strategies Targeting TAFI-mediated Vascular Remodeling in Hemophilic Arthropathy

Year:
-
Grants:
Judith Graham Pool Postdoctoral Research Fellowship
Hemophilic Arthropathy
Pain
Author(s):
Tine L. Wyseure

Dr. Tine Wyseure obtained her Master’s degree in Drug Discovery and Development, and earned her Ph.D. in Pharmaceutical Sciences at the University of Leuven, Belgium. Since 2015, she has been a research associate in the lab of Dr. Laurent Mosnier at The Scripps Research Institute in San Diego. Dr. Wyseure’s 2016 JGP research fellowship award project is focused on investigating the effects of impaired TAFI activation in hemophilia on the progression of hemophilic joint disease. The lack of active TAFI worsens joint bleeding and chronic inflammation and drives the striking development of fragile blood vessels in diseased joints. In search of the missing link, Dr. Wyseure has discovered a novel paradigm on how the formation of new blood vessels is controlled by TAFI and suggests that patients with hemophilia may lack this control switch, causing the formation of unstable and leaky blood vessels.

Efficacy, safety and pharmacokinetics of once-weekly prophylactic emicizumab (ACE910) in pediatric persons (<12 years) with hemophilia A with inhibitors: interim analysis of single-arm, multicenter, open-label, phase 3 study (HAVEN 2)

Efficacy, safety and pharmacokinetics of once-weekly prophylactic emicizumab (ACE910) in pediatric persons (<12 years) with hemophilia A with inhibitors: interim analysis of single-arm, multicenter, open-label, phase 3 study (HAVEN 2)

AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
RESEARCHERS:
Guy Young, Johannes Oldenburg, Ri Liesner, Victor Jiménez-Yuste, Maria Elisa Mancuso, Tiffany Chang, Marianne Uguen, Christophe Dhalluin, Christophe Schmitt, Sabine Fuerst-Recktenwald, Midori Shima, Rebecca Kruse-Jarres
A Multi-System Evaluation of von Willebrand Factor Function in Type I von Willebrand Disease Mutations

A Multi-System Evaluation of von Willebrand Factor Function in Type I von Willebrand Disease Mutations

Year:
-
Grants:
Judith Graham Pool Postdoctoral Research Fellowship
Von Willebrand Disease
Author(s):
Christopher Ng

Dr. Christopher Ng was a pediatric hematology/oncology fellow at the University of Colorado - Anschutz Medical Campus. Dr. Ng attended medical school at the Keck School of Medicine at the University of Southern California and completed his pediatrics residency at the University of Washington/Seattle Children's Hospital. Dr. Ng received the NHF-Baxalta Clinical Fellowship in 2013. Dr. Ng's 2015 JGP research fellowship award project focused on a multi-system evaluation of von Willebrand factor function in Type 1 von Willebrand Disease mutations.